Agenda
- Jump to:
- At a Glance
- Day 1
- Day 2
- Print-friendly Format
Day 1 - Tuesday, May 30, 2017
8:00 |
Registration Opens and Refreshments Served |
9:00 |
Opening Remarks from Chair |
9:15 |
Opening Keynote: Canada’s Pharmaceutical Industry in a Global Context |
9:45 |
Creating a Two-Way Street Between Industry and Reviewers |
10:45 |
Networking Refreshment Break Sponsored by: Innomar Strategies |
11:00 |
The Path from Clinical Trial to Patient Access |
11:45 |
Leveraging Big Data to Provide Real World Evidence of Health Outcomes |
12:30 |
Networking Luncheon for Delegates and Speakers |
1:30 |
Using Effective Treatment and Outcome Evaluations through the Patient Support Program to Support Market Access Strategy |
2:15 |
Policy Environments that Encourage Innovation in Pharma: An International Comparison |
3:00 |
Networking Refreshment Break Sponsored by: Innomar Strategies |
3:15 |
PMPRB Regulatory Changes – Outlook and Implications |
4:00 |
Ensuring Access: Orphan Drugs in Canada |
4:45 |
Chair’s Closing Remarks and Conference Adjourns |
Day 2 - Wednesday, May 31, 2017
8:30 |
Refreshments Served |
9:00 |
Opening Remarks from Chair |
9:15 |
Opening Address: The Patient Voice in Pharma |
9:45 |
Enabling Beneficial Outcomes by Implementing Patient-Centred Strategies |
10:30 |
Networking Refreshment Break Sponsored by: Pivina |
11:00 |
pCPA: What does the Future Hold for Negotiations in Canada? |
11:45 |
Thinking Beyond the Deal: A Strategic Approach to the pan-Canadian Pharmaceutical Alliance (pCPA) |
12:30 |
Networking Luncheon for Delegates and Speakers |
1:30 |
Plan Sponsors: Design Change and Pharma |
2:15 |
Drug Regulatory Review and Access in Canada and Abroad – Best Practices |
3:00 |
Conference Concludes |
Day 1 - Tuesday, May 30, 2017
8:00 |
Registration Opens and Refreshments Served |
9:00 |
Opening Remarks from ChairKaitlyn Proulx |
9:15 |
Opening Keynote: Canada’s Pharmaceutical Industry in a Global ContextTerry Creighton |
9:45 |
Creating a Two-Way Street Between Industry and ReviewersBrent Fraser DR. CHANDER M. SEHGAL, MBA, MD When, and what information is available is an issue of concern for many involved with the review of submissions for new drugs in Canada. There must be a balance between corporate confidentiality and transparency; how do we negotiate this line, and what is the impact?
|
10:45 |
Networking Refreshment Break Sponsored by: Innomar Strategies |
11:00 |
The Path from Clinical Trial to Patient AccessSusan Marlin Clinical trials, done in Canada, can have a number of positive effects on our economy, research institutions, patients and our health care system. There is now more than ever a focus on increasing the number of trials happening here, completing them faster and more efficiently, and getting therapies to patients. This session will review:
|
11:45 |
Leveraging Big Data to Provide Real World Evidence of Health OutcomesBrad Millson Randomized controlled trials (RCTs) are considered the gold standard for evidence of a therapy’s clinical efficacy. However, the clinical impact demonstrated in RCTs are not necessarily generalizable, due to real-world patient variability. Fortunately, the growing volume, quality, and accessibility of administrative healthcare data, such as electronic health records, can provide critical insights on a treatment’s long-term impact. It is also expanding the vision of how evidence is generated and applied through the entire lifecycle of a new medical technology. The presentation will cover:
|
12:30 |
Networking Luncheon for Delegates and Speakers |
1:30 |
Using Effective Treatment and Outcome Evaluations through the Patient Support Program to Support Market Access StrategySandra Anderson
|
2:15 |
Policy Environments that Encourage Innovation in Pharma: An International ComparisonJason Field Innovation is crucial. Not only does the pharmaceutical industry fulfill a duty to public health, it also offers growth opportunities for the Canadian economy. Ensure that your reimbursement strategy reflects the multiplier effect of innovation.
|
3:00 |
Networking Refreshment Break Sponsored by: Innomar Strategies |
3:15 |
PMPRB Regulatory Changes – Outlook and ImplicationsW. Neil Palmer The federal Minister of Health has announced sweeping changes to the Patented Medicine Prices Review Board (PMPRB) regulatory framework that will result significant changes in the way PMPRB regulates drug prices in Canada. The Minister’s clear objective is lower prices for patented medicines in Canada. In addition to the regulatory changes, the PMPRB has been conducting consultations on its Excessive Price Guidelines. Together, the new regulations and guidelines will dramatically change how PMPRB regulates prices in Canada. This interactive session will outline the likely changes coming to PMPRB, the implications to manufacturers and foster discussion on the prospects for drug pricing in Canada. Specific topics will include:
|
4:00 |
Ensuring Access: Orphan Drugs in CanadaDurhane Wong-Rieger Payers, regulators, and patients continue to struggle with the cost of specialty medication. Drugs, such as those needed to treat Hepatitis C, account for a great deal of the expense of pharmaceuticals in Canada. How can all actors collaborate to ensure access to Canadians?
|
4:45 |
Chair’s Closing Remarks and Conference Adjourns |
Day 2 - Wednesday, May 31, 2017
8:30 |
Refreshments Served |
9:00 |
Opening Remarks from ChairKaitlyn Proulx |
9:15 |
Opening Address: The Patient Voice in PharmaNorma Beauchamp Norma Beauchamp |
9:45 |
Enabling Beneficial Outcomes by Implementing Patient-Centred StrategiesGenevieve Pelletier Even the perfect drug, ultimately, cannot be effective if it’s administered incorrectly. Pharma has a vested interest in ensuring that patients are taking their products consistently and properly.
|
10:30 |
Networking Refreshment Break Sponsored by: Pivina |
11:00 |
pCPA: What does the Future Hold for Negotiations in Canada?Anchalee Srisombun The pCPA has played an integral role in lowering drug costs for public payers in Canada, but what will 2017 mean for the organization? Many in the industry have been discussing the possibility of private payers entering the association and how that could impact prices.
|
11:45 |
Thinking Beyond the Deal: A Strategic Approach to the pan-Canadian Pharmaceutical Alliance (pCPA)Paul Henricks Norma Beauchamp Norma Beauchamp Chris Goguen John Paul Dowson Sang Mi Lee
|
12:30 |
Networking Luncheon for Delegates and Speakers |
1:30 |
Plan Sponsors: Design Change and PharmaMartin Chung Adapting to the Evolution of Plan Design and Its Impact on Market Access and Reimbursement
|
2:15 |
Drug Regulatory Review and Access in Canada and Abroad – Best PracticesUli Broedl The drug to market process in Canada is one of the longest in the world. How can pharmaceutical companies prepare for, and mitigate delays? What international best practices can Canada adopt to maintain a competitive pharmaceutical industry?
|
3:00 |
Conference Concludes |